Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis. Issue 3 (3rd January 2020)

• Record Type: Journal Article
• Authors: Xiao, Xinhua; Wang, Changjiang; Lai, Xiaoyang; Zhang, Bin; Gu, Liqun; Hou, Jianing; Zhou, Zhiguang
• Is Part Of: Journal of diabetes investigation. Volume 11:Issue 3(2020)
• Page Start: 647
• Page End: 652
• Publication Date: 2020-01-03
• Subjects: Composite end‐point -- Dulaglutide -- Type 2 diabetes; Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.13187
• Languages: English
• ISSNs: 2040-1116

Abstract

Abstract: Aims/Introduction: To assess the effect of dulaglutide (DU) 1.5/0.75 mg in comparison with glimepiride (GLIM) or insulin glargine (GLAR) on the composite end‐point in Chinese type 2 diabetes patients. Materials and Methods: Post‐hoc analyses of two randomized phase III trials (NCT01644500 and NCT01648582) were carried out using Fisher&#39;s exact test. The primary composite end‐point was the number of patients reaching glycated hemoglobin (HbA1c) &lt;7.0%, without weight gain and hypoglycemia. Secondary composite end‐points included the number of patients reaching HbA1c &lt;7.0% without weight gain and HbA1c &lt;7.0% without hypoglycemia. Results: Data of 1, 147 Chinese type 2 diabetes patients were analyzed (NCT01644500 = 556; NCT01648582 = 591). In each analyzed trial, 40–48% of patients received DU (1.5 mg), 30–39% of patients received DU (0.75 mg) and 15–20% of patients on active comparators (GLIM/GLAR) reached the primary composite end‐point at week 26 ( P &lt; 0.001 for DU vs GLIM/GLAR). At 52 weeks, 26% of patients that received DU (1.5 mg), 23% of patients that received DU (0.75 mg) and 7% of patients that received GLAR attained the primary composite end‐point ( P &lt; 0.001 for DU vs GLAR). A similar trend of results was found for secondary composite end‐points. Conclusions: Dulaglutide is found to be an effective therapeutic alternative for Chinese type 2 diabetes patients. Compared with GLIM/GLAR, significantly greater proportions of patients on DU attained the HbA1c target of &lt;7.0% without weight gain or hypoglycemia. Abstract : The present post‐hoc analysis was carried out using data from two randomized, multinational, parallel‐arm and non‐inferiority phase III trials (AWARD‐CHN1 study [NCT01644500] and AWARD‐CHN2 study [NCT01648582] of dulaglutide in patients with type 2 diabetes.